Document ID: chunk:federal_register_of_legislation:F2024C01066:reg:13
Version: federal_register_of_legislation:F2024C01066
Segment Type: reg
Provision Reference: reg 13
Character Range: 28458–30081

13  Procedures for making payments in respect of claims
 (1) For the purposes of subparagraph 99AAA(8)(e)(ii) of the Act, this section defines the procedures to be followed by the Chief Executive Medicare, on behalf of the Secretary, in making payments in respect of claims by an approved supplier in relation to the supply of pharmaceutical benefits.
 (2) The Chief Executive Medicare must ensure that:
 (a) payments are made by:
 (i) an electronic funds transfer from the Commonwealth to the account at a financial institution nominated in writing by the approved supplier; or
 (ii) any other form of electronic payment from the Commonwealth to the approved supplier nominated in writing by the approved supplier; and
 (b) for any approved supplier—a statement of account including information about non-ACSS payments is given to the approved supplier in respect of each claim for payment; and
 (c) for an approved supplier who is an approved pharmacist—a statement of account including information about ACSS payments covered by the statement of account is given to the approved pharmacist.
Example: For the purposes of subparagraph (a)(ii), other forms of electronic payment include PayID and payments through mobile telephone applications.
 (3) A statement of account referred to in paragraph (2)(c) is not required to relate to a particular claim period and may include information about ACSS payments made in respect of supplies of pharmaceutical benefits made in different claim periods.
Note: Approved pharmacists are the only approved suppliers who are entitled to ACSS payments – see section 99AAAA of the Act.